Clinzucia Uses

What is the dose of your medication?
sponsored

What is Clinzucia?

Clinzucia belongs to the family of medicines called antibiotics.

Topical Clinzucia is used to help control acne. It may be used alone or with one or more other medicines that are used on the skin or taken by mouth for acne.

Topical Clinzucia may also be used for other problems as determined by your doctor.

Clinzucia is available only with your doctor's prescription.

Clinzucia indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Clinzucia (Clinzucia palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.

Clinzucia is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting Clinzucia the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).

Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection.

Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Pneumococci: Serious respiratory tract infections.

Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to Clinzucia.

In Vitro Susceptibility Testing

A standardized disk testing procedure2 is recommended for determining susceptibility of aerobic bacteria to Clinzucia. A description is contained in the Clinzucia® Susceptibility Disk (Clinzucia) insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for both anaerobic and aerobic bacteria. When the directions in the Clinzucia® Susceptibility Powder insert are followed, an MIC (minimal inhibitory concentration) of 1.6 mcg/mL may be considered susceptible; MICs of 1.6 to 4.8 mcg/mL may be considered intermediate and MICs greater than 4.8 mcg/mL may be considered resistant.

Clinzucia Susceptibility Disks 2 mcg. See package insert for use.

Clinzucia Susceptibility Powder 20 mg. See package insert for use.

For anaerobic bacteria the minimal inhibitory concentration (MIC) of Clinzucia can be determined by agar dilution and broth dilution (including microdilution) techniques. If MICs are not determined routinely, the disk broth method is recommended for routine use. THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clinzucia and other antibacterial drugs, Clinzucia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

How should I use Clinzucia?

Use Clinzucia cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Clinzucia cream.

Uses of Clinzucia in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Use: Labeled Indications

Bone and joint infections: Treatment of bone and joint infections, including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections caused by susceptible organisms.

Gynecological infections: Treatment of gynecologic infections, including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Intraabdominal infections: Treatment of intraabdominal infections, including peritonitis and intraabdominal abscess caused by susceptible anaerobic organisms.

Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia, empyema, and lung abscess caused by susceptible anaerobes, Streptococcus pneumoniae, other streptococci (except Enterococcus faecalis), and S. aureus.

Septicemia: Treatment of septicemia caused by S. aureus, streptococci (except E. faecalis), and susceptible anaerobes.

Skin and soft tissue infection: Treatment of skin and soft tissue infection caused by Streptococcus pyogenes, S. aureus, and susceptible anaerobes.

Off Label Uses

Anthrax

Based on the Centers for Disease Control and Prevention (CDC) expert panel meetings on prevention and treatment of anthrax in adults, Clinzucia is an effective and acceptable alternative for postexposure prophylaxis or treatment of cutaneous anthrax; it is also a first-line option, in combination with other antimicrobials, for the treatment of systemic anthrax. Alternative regimens have also been suggested for other patient populations with anthrax, including injectable drug users who develop injectional anthrax.

Streptococcal (group A) pharyngitis and chronic carriage

Based on the IDSA guidelines for the diagnosis and management of group A streptococcal pharyngitis, Clinzucia is an effective and recommended alternative agent for the treatment of streptococcal pharyngitis and an option for treatment of chronic group A streptococcal carriage.

Surgical prophylaxis

Based on the American Society of Health-System Pharmacists (ASHP) clinical practice guidelines for antimicrobial prophylaxis in surgery, Clinzucia, given as an alternative antibiotic in patients with beta-lactam allergy requiring surgical prophylaxis, is effective and recommended for a number of surgical procedures.

Toxoplasma gondii encephalitis and pneumonitis (treatment/long-term maintenance)

Based on the US Department of Health and Human Services guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents and the American Society of Transplantation Infectious Diseases Community of Practice guidelines on parasitic infections in solid organ transplantation, Clinzucia (with pyrimethamine and leucovorin) is an effective and recommended alternative regimen for the treatment and long-term maintenance therapy of Toxoplasma gondii encephalitis and pneumonitis.

Clinzucia description

sponsored

Clinzucia is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

Clinzucia phosphate is a water soluble ester of Clinzucia and phosphoric acid.

Clinzucia phosphate is L-threo-α-D-galacto-Octopyranoside, methyl 7-chloro-6, 7, 8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.

The molecular formula is C18H34CIN2O8PS and the molecular weight is 504.96.

Clinzucia hydrochloride is the hydrated hydrochloride salt of Clinzucia. Clinzucia hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside monohydrochloride.

Clinzucia palmitate hydrochloride is a water soluble salt of ester of Clinzucia and palmitic acid. Clinzucia palmitate hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-palmitate monohydrochloride.

Clinzucia dosage

sponsored

Clinzucia Dosage

Generic name: Clinzucia HYDROCHLORIDE 75mg

Dosage form: capsule

See also:

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

If significant diarrhea occurs during therapy, this antibiotic should be discontinued.

Adults: Serious infections – 150 to 300 mg every 6 hours. More severe infections – 300 to 450 mg every 6 hours. Pediatric Patients: Serious infections – 8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses. More severe infections – 16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses.

To avoid the possibility of esophageal irritation, Clinzucia HCl Capsules should be taken with a full glass of water.

Serious infections due to anaerobic bacteria are usually treated with Clinzucia PHOSPHATE® Sterile Solution. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with Clinzucia HCl Capsules.

In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.

More about Clinzucia (Clinzucia)

Consumer resources

Professional resources

Other formulations

Related treatment guides

Clinzucia interactions

See also:
What other drugs will affect Clinzucia?

With simultaneous use of Clinzucia with theophylline, aminophylline, caffeine, there is an increase in their concentration in blood plasma and thus increases the risk of toxic effects.

Erythromycin increases the concentrations of cyclosporine in the blood plasma and may increase the risk of nephrotoxicity.

Drugs that block tubular secretion prolongs T1/2 of erythromycin.

Incompatible with lincomycin, Clinzucia and chloramphenicol (antagonism).

Clinzucia reduces the bactericidal action of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems).

With simultaneous use of erythromycin increases the concentration of theophylline.

At the same time receiving chemotherapy, which is carried metabolism in the liver (carbamazepine, valproic acid, hexobarbital, phenytoin, alfentanil, dizopiramid, lovastatin, bromocriptine), may increase the concentration of these drugs in plasma (an inhibitor of microsomal liver enzymes).

IV injection of erythromycin increases the effects of ethanol (accelerating gastric emptying and decrease the duration of alcohol dehydrogenase in the gastric mucosa).

Erythromycin reduces the clearance of triazolam and midazolam and therefore may increase the pharmacological effects of benzodiazepines.

At the same time taking with terfenadine or astemizole may develop arrhythmias (fibrillation and ventricular flutter, ventricular tachycardia, until death); with dihydroergotamine or non hydrated ergot alkaloids may vasoconstriction to spasm, dysesthesia.

With simultaneous application Clinzucia slows elimination (increases the effect) of methylprednisolone, felodipine and anticoagulants of cumarine series.

In a joint appointment with lovastatin increased rhabdomyolysis.

Erythromycin increases the bioavailability of digoxin.

Erythromycin reduces the effectiveness of hormonal contraceptives.

Clinzucia side effects

See also:
What are the possible side effects of Clinzucia?

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

A total of 439 subjects with mild to moderate acne vulgaris were treated once daily for 12 weeks with Clinzucia Foam.

The incidence of adverse reactions occurring in ≥1% of the subjects in clinical trials comparing Clinzucia Foam and its vehicle is presented in Table 1.

Table 1: Adverse Reactions Occurring in ≥1% of Subjects

Adverse Reactions Number (%) of Subjects
Clinzucia Foam

N = 439

Vehicle Foam

N = 154

Headache 12 (3%) 1 (1%)
Application site burning 27 (6%) 14 (9%)
Application site pruritus 5 (1%) 5 (3%)
Application site dryness 4 (1%) 5 (3%)
Application site reaction, not otherwise specified 3 (1%) 4 (3%)

In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to Clinzucia Foam.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of Clinzucia Foam: application site pain, application site erythema, diarrhea, urticaria, abdominal pain, hypersensitivity, rash, abdominal discomfort, nausea, seborrhea, application site rash, dizziness, pain of skin, colitis (including pseudomembranous colitis), and hemorrhagic diarrhea. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in association with the use of topical formulations of Clinzucia.

Orally and parenterally administered Clinzucia have been associated with severe colitis, which may end fatally.

Clinzucia contraindications

See also:
What is the most important information I should know about Clinzucia?

You should not use this medication if you are allergic to Clinzucia or lincomycin (Bactramycin, L-Mycin, Lincocin).

Do not take Clinzucia together with erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole, and others).

Before using Clinzucia, tell your doctor if you have kidney disease, liver disease, an intestinal disorder such as colitis or Crohn's disease, or a history of asthma, eczema, or allergic skin reaction.

Take this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Clinzucia will not treat a viral infection such as the common cold or flu.

Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking Clinzucia and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.

To be sure this medication is not causing harmful effects, your blood may need to be tested often. Your kidney or liver function may also need to be tested. Visit your doctor regularly.

If you need surgery, tell the surgeon ahead of time that you are using Clinzucia. You may need to stop using the medicine for a short time.



Active ingredient matches for Clinzucia:

Clindamycin


Unit description / dosage (Manufacturer)Price, USD
150 mg x 8's
300 mg x 8's
300 mg x 1's
600 mg x 1's
Clinzucia 150mg CAP / 8
Clinzucia 300mg CAP / 8
Clinzucia 300mg AMP / 1
Clinzucia 600mg AMP / 1
CLINZUCIA 300MG CAPSULE 1 strip / 8 capsules each (United Biotech Pvt Ltd)$ 3.17
CLINZUCIA 300MG INJECTION 1 vial / 2 ML injection each (United Biotech Pvt Ltd)$ 1.31
CLINZUCIA cap 150 mg x 8's (United Biotech)
CLINZUCIA cap 300 mg x 8's (United Biotech)
CLINZUCIA inj 300 mg x 1's (United Biotech)
CLINZUCIA inj 600 mg x 1's (United Biotech)
Clinzucia 150mg CAP / 8
Clinzucia 300mg CAP / 8
Clinzucia 300mg AMP / 1
Clinzucia 600mg AMP / 1
Clinzucia 300mg Capsule (United Biotech Pvt Ltd)$ 0.40
Clinzucia 300mg Injection (United Biotech Pvt Ltd)$ 0.65

List of Clinzucia substitutes (brand and generic names):

CLINZUCIA 600MG INJECTION 1 vial / 1 injection each (United Biotech Pvt Ltd)$ 2.45
Cliz 300 mg x 50's (Integra)$ 38.89
Clod-SL Clobetasol 0.05 % w/w, salicylic acid 6 % w/w. OINT / 15g (Daksh)$ 0.86
Clod-Sl Clobetasol 0.05 % w/w, salicylic acid 6 % w/w. CRM / 15g (Daksh)$ 0.86
CLOD-SL cream 15g (Daksh)$ 0.86
Clod-Sl Clobetasol 0.05 % w/w, salicylic acid 6 % w/w. CRM / 15g (Daksh)$ 0.86
Clodale Clotrimazole 100 mg, clindamycin 100 mg, lactobacillus 1.2 billioncells. SUPP / 7 (Allen Dale)$ 1.59
CLODALE supp 7's (Allen Dale)$ 1.59
CLZ 300 mg Capsule (F.C. Remedies)$ 0.35
Comdasin 300 mg x 30's (Combiphar)$ 17.48
Comdasin Solution 1 % x 30 mL$ 3.41
Croclin-A Clindamycin phosphate 10 mg, adapalene 1 mg. T-GEL / 10g (Cronus)$ 1.11
CROCLIN-A topical gel 10g (Cronus)$ 1.11
Ctop 1% w/w GEL / 20g (Intas Laboratories Pvt Ltd)$ 0.67
1 % w/w x 20g (Intas Laboratories Pvt Ltd)$ 0.67
Ctop Skin 20 gm Gel (Intas Laboratories Pvt Ltd)$ 0.67
Ctop 100 mg Injection (Intas Laboratories Pvt Ltd)$ 0.86
CTOP 1% GEL 1 tube / 20 GM gel each (Intas Laboratories Pvt Ltd)$ 0.32
CTOP topical gel 1 % w/w x 20g (Intas Laboratories Pvt Ltd)$ 0.67
Ctop 1% Gel (Intas Laboratories Pvt Ltd)$ 0.32
Gel; Topical; Clindamycin Phosphate 1% (Valeant)
D'Acne 1% w/w GEL / 10g (Glenmark (Gracewell))$ 1.25
D'ACNE topical gel 1 % w/w x 10g (Glenmark (Gracewell))$ 1.25
Dacin-F 150 150 mg x 10 x 10's (Farmaline)
Dacin-F 300 300 mg x 10 x 10's (Farmaline)
Daclin Acne 1 % x 10 g x 1's
Daclin-300 300 mg x 50's$ 26.66
Daklin 150mg CAP / 100 (Synmedic)
Daklin 300mg CAP / 100 (Synmedic)

References

  1. PubChem. "clindamycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  2. DrugBank. "clindamycin". http://www.drugbank.ca/drugs/DB01190 (accessed September 17, 2018).
  3. MeSH. "Protein Synthesis Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Clinzucia are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clinzucia. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 2 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved